The announcement of the high efficacy of the vaccine developed by Pfizer and BioNTech and the request by these companies for emergency authorization for its use to the United States Food and Drug Administration (FDA) pI would like to advance the terms initially foreseen for its application among the population.
Dr. Moncef Slaoui, head of the country’s COVID-19 vaccination campaign, stated on CNN that the first US citizens could be vaccinated in the coming weeks. Specifically, the virologist points to the date of December 11 as the possible start of vaccination of the population.
Dr. Moncef Slaoui, chief scientific adviser of Operation Warp Speed, says first Americans could receive a Covid-19 vaccine by December. “So I would expect, maybe, on day two after approval … hopefully the first people will be immunized across the United States.” #CNNSOTU pic.twitter.com/UvQpPi0pl9
– State of the Union (@CNNSotu) November 22, 2020
A committee of FDA experts will evaluate the request of Pfizer and BioNTech on December 10 and, if approved, the vaccine would begin to be applied to citizens as early as the next day, December 11, Slaoui revealed.
“Our plan is to be able to send vaccines to immunization sites within 24 hours of approval,” explained the head of the vaccination campaign against the United States coronavirus, who added that for this reason it could surely start to apply “on the second day after approval, on December 11th or 12th.”
The priority groups, in the first instance
The first people to be vaccinated would be the groups considered priority, such as health professionals, the elderly and those with other medical conditions, as the experts insist, who recall that initially there will not be enough doses of the vaccine for all citizens of the country.
Pfizer and BioNTech submitted the application to the FDA for the authorization of their vaccine on November 20 after confirming in human trials that the effectiveness of their vaccine is 95% and that it did not present health risks. The European Medicines Agency, for its part, will also study the case soon and could approve its use in the second half of December.